8 unknown. 8 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 8 |
| Phase 1 | 2 | Unknown 2 |
| Phase 3 | 2 | Unknown 2 |
Follow Cholestasis: new trials by email Literature Review of Cholestasis trials Research Report on Cholestasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) TQA3526, Placebo to match TQA3526 - Primary Biliary Cirrhosis | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 130 | 2020-03-20 | 2020-02-20 |
| Probiotics in PBC Patients of Poor Response to UDCA Probiotic, Placebo - Primary Biliary Cholangitis (PBC) | Phase 2 | Unknown | Sun Yat-sen University | 60 | 2020-01-20 | 2020-01-07 |
| Metformin in Intrahepatic Cholestasis of Pregnancy Metformin, Ursodeoxycholic Acid - Intrahepatic Cholestases, Pregnancy Complications | Phase 2 / Phase 3 | Unknown | Epsom and St Helier University Hospitals NHS Trust | 40 | 2019-01-01 | 2018-07-26 |
| Pilot Study of FFP104 Dose Escalation in PBC Subjects FFP104 - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Unknown | Fast Forward Pharmaceuticals | 24 | 2015-05-01 | 2016-08-24 |
| Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis conventional plus UC-MSC treatment, Conventional plus placebo treatment - Primary Biliary Cirrhosis | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 100 | 2011-10-01 | 2013-05-31 |
| Minimization of IntraLipid Versus Omegaven Omegaven, Lipid minimization - Cholestasis, Parenteral Nutrition Associated Liver Disease (PNALD) | Phase 2 / Phase 3 | Unknown | Children's & Women's Health Centre of British Columbia | 40 | 2010-12-01 | 2011-09-07 |
| Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease Omegaven Therapy - Short Bowel Syndrome, Cholestasis | Phase 2 | Unknown | Amarnath, Rathna, M.D. | 20 | 2009-03-01 | 2012-12-03 |
| Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease ursodiol - Cystic Fibrosis, Gastrointestinal Diseases | Phase 2 | Unknown | National Center for Research Resources (NCRR) | 20 | 1995-11-01 | 2005-06-24 |
Liver Cirrhosis, Biliary (4) · Cholestasis, Intrahepatic (1) · Cystic Fibrosis (1) · Gastrointestinal Diseases (1) · Genetic Diseases, Inborn (1) · Inflammation (1) · Pregnancy Complications (1) · Rare Diseases (1) · Respiratory Tract Diseases (1) · Short Bowel Syndrome (1)
Bile Duct Diseases (8) · Biliary Tract Diseases (8) · Digestive System Diseases (8) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Liver Diseases (5) · Cholestasis, Intrahepatic (4) · Fibrosis (4) · Liver Cirrhosis (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Infant, Newborn, Diseases (1)
Ursodeoxycholic Acid (2) · Congresses as Topic (1) · Metformin (1) · Probiotics (1) · fish oil triglycerides (1)
Amarnath, Rathna, M.D. (1) · Beijing 302 Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's & Women's Health Centre of British Columbia (1) · Epsom and St Helier University Hospitals NHS Trust (1) · Fast Forward Pharmaceuticals (1) · National Center for Research Resources (NCRR) (1) · Sun Yat-sen University (1)
China (3) · United States (2) · Canada (1) · Netherlands (1) · United Kingdom (1)
Avash J Singh, MD (1) · Bingliang Lin, MD (1) · Fu-Sheng Wang, professor (1) · Hassan Shehata, FRCPI, FRCOG (1) · Rebecca Sherlock, MD (1) · Susan Albersheim, MD, PhD (1) · Terra R Varner, PharmD (1) · William Balistreri (1)
2014 (1)